

# OMICS GROUP



OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over **400** leading-edge peer reviewed Open Access Journals and organizes over **300** International Conferences annually all over the world. OMICS Publishing Group journals have over **3 million** readers and the fame and success of the same can be attributed to the strong editorial board which contains over **30000** eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than **1000** International Societies to make healthcare information Open Access.

# OMICS Journals are welcoming Submissions

OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions.

The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

**For more details please visit our website:**  
**<http://omicsonline.org/Submitmanuscript.php>**



## **Shouji Shimoyama, MD. PhD.**

President  
Gastrointestinal Unit,  
Settlement Clinic  
Tokyo, Japan.  
[Shimoyama@apost.plala.or.jp](mailto:Shimoyama@apost.plala.or.jp)



## **General: My research topics are:**

Genetic alterations that may

- affect efficacy of treatment against malignancies.
- help predict adverse events.

Interactions of targeted molecules that may cause treatment resistance.



## Research concepts:

Elucidation of genetic alterations affecting efficacy and/or adverse events that could help select right patients to the right treatment.

This could ultimately establish molecularly guided personalized treatment.



## Fluorouracil:

Genetic alterations of enzymes that are involved in fluorouracil metabolism.

Shimoyama S.

Chemotherapy for gastric cancer. Current achievements in survival improvement and therapy individualization. In: Gastric Cancer Research Trends. Editor: Tompkins MB. Nova Science Publisher NY, USA, 2008, pp 1-40

Shimoyama S.

Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment. J Gastroenterology and Hepatology. 2009, 24, 970-981.





## Cisplatin:

Genetic alterations of enzymes that are involved in cisplatin metabolism.

Shimoyama S.

Cisplatin: Its Clinical Application and Therapy Individualization in Gastric and Esophageal Cancers.

In: Cisplatin: Pharmacology, Clinical Uses and Adverse Effects

Editors: Toshiko Kojima and Yoko Morita

Nova Science Publisher NY, USA, 2012, pp 97-122.



## Irinotecan:

Interethnic difference of drug metabolism due to genetic polymorphism relevant to enzymatic activity.

Shimoyama S.

Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.

World J Gastrointest Surg 2010; 2: 14-21.





## **BRAF:**

Overview of BRAF mutations that could help understanding of resistance to anti-BRAF therapy.

Shimoyama S.

BRAF mutations and their implications in molecular targeting therapies for gastrointestinal cancers.

Editorial: J Pharmacogenom Pharmacoproteomics 2011, 2: e102.

<http://www.omicsonline.org/ArchiveJPP/CurrentissueJPP.php>



## **Trastuzumab:**

Molecular interactions that provide hints to overcome trastuzumab resistance.

Shimoyama S.

Unraveling trastuzumab and lapatinib in gastric cancer. Future steps.

Mol Clin Oncol 2014; 2, 175-181.

# Pharmacogenomics & Pharmacoproteomics Related Journals

[Journal of Molecular and Genetic Medicine](#)

[Journal of Data Mining in Genomics & Proteomics](#)

[Journal of Proteomics & Bioinformatics](#)



# Pharmacogenomics & Pharmacoproteomics Related Conferences

[2<sup>nd</sup> International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics](#)

[4<sup>th</sup> International Conference on Proteomics & Bioinformatics](#)

[2<sup>nd</sup> International Conference on Genomics & Pharmacogenomics](#)



# OMICS Group Open Access Membership

OMICS publishing Group Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors.

For more details and benefits, click on the link below:

<http://omicsonline.org/membership.php>

